PSME4

Proteasome activator complex subunit 4 · Q14997 · PSME4 on Sugi Atlas →

0 patent compounds predicted against PSME4, 0 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours

Clinical trials — most relevant to PSME4 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
A Prospective, Placebo Controlled, Double-Blind, Cross-over Study on the Effects of a Probiotic Preparation (VSL#3) on Metabolic Profile, Intestinal Permeability, Microbiota, Cytokines and Chemokines Expression and Other Inflammatory Markers in Pediatric Patients With Crohn's Disease PHASE4UNKNOWN
Doxorubicin and Bortezomib in Treating Patients With Liver Cancer PHASE2COMPLETED
Desferal Administration to Improve the Impaired Reaction to Hypoxia in Diabetes PHASE2UNKNOWN
Biologic Correlative Taxotere/AC PHASE2COMPLETED
Phase II Study of Vandetanib in Individuals With Kidney Cancer PHASE2COMPLETED
Melpida: Recombinant Adeno-associated Virus (serotype 9) Encoding a Codon Optimized Human AP4M1 Transgene (hAP4M1opt) PHASE1/PHASE2RECRUITING
Relapsed and/or Refractory Non-Hodgkin Lymphoma Study PHASE2WITHDRAWN
PS-341 and Radiation to Treat Advanced Cancer of the Head and Neck PHASE1COMPLETED
PS-341 in Treating Patients With Advanced Solid Tumors or Lymphoma PHASE1COMPLETED
Extended Infusion Carfilzomib on a Weekly Schedule in Patients With Advanced Solid Tumors PHASE1COMPLETED
Study of Patients With Stage IV Malignant Melanoma Using PS-341 (Bortezomib, Velcade) and Interferon-alpha-2b in Malignant Melanoma PHASE1COMPLETED
Bortezomib and Carboplatin in Treating Patients With Recurrent or Progressive Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer PHASE1COMPLETED
Evaluation of Proteasome as a Marker of Hepatocellular Carcinoma in Cirrhotic Patients Following Curative Treatment nanUNKNOWN
Differential Gene Expression of Liver Tissue and Blood From Individuals With Chronic Viral Hepatitis nanUNKNOWN
Effect of Dietary Nitrate on Immobilization-induced Changes in Skeletal Muscle in Young Healthy Men nanRECRUITING
Low Dose Melphalan and Bortezomib for AML and High-Risk MDS nanCOMPLETED
Quantification of GADD34 Expression in RA nanCOMPLETED
Clinical Study of 68Ga-DOTA-BLP PET Imaging in Noninvasive Diagnosis of Malignant Tumors nanNOT_YET_RECRUITING
The PREServation of MUScle Function in Critically Ill Patients (PRESMUS) nanUNKNOWN
Mitochondrial Activity and Myosteatosis in the Cachexia of Cancers of the Upper Aerodigestive Tract nanUNKNOWN
Biomarkers in Tumor Samples From Younger Patients With Neuroblastoma nanCOMPLETED
Establishment of Human Cellular Disease Models for Wilson Disease nanCOMPLETED
Autophagy in Systemic Lupus Erythematosus nanUNKNOWN
Inhibition of SENP1 for the Suppression of OS Growth and Metastasis nanUNKNOWN
Cardiovascular Complications of Carfilzomib Treatment nanUNKNOWN
Safety and Tolerability of a Nutritional Formula Designed to Aid in Maintenance of Muscle During Periods of Caloric Restriction in Adults nanNOT_YET_RECRUITING
Exercise Therapy to Reduce Heart Failure Symptoms; Sorting Mechanisms of Benefit nanCOMPLETED
Maximizing Mechanisms of Muscle Hypertrophy to Combat Sarcopenia in Older Adults nanCOMPLETED
Impact of O6-methylguanine-DNA Methyltransferase (MGMT) Promoter Methylation and MGMT Expression on Dacarbazine Treated Sarcoma Patients (MGMT) nanUNKNOWN
Exploring Novel Biomarkers of ICU-AW in Mechanically Ventilated Children at the Molecular Level nanENROLLING_BY_INVITATION

Related proteins — ESM-2 sequence neighbours (a PSME4 binder may also engage these)

ProteinNameSimilarity
F1MKX4 1.000 F1MKX4 →
F1R2X6 0.998 F1R2X6 →
Q5SSW2 0.997 Q5SSW2 →
Q6NRP2 0.996 Q6NRP2 →
F1QFR9 0.994 F1QFR9 →
Q6GQ80 0.984 Q6GQ80 →
Q6A026 0.983 Q6A026 →
PDS5A Sister chromatid cohesion protein PDS5 homolog A 0.982 landscape →
Q6TRW4 0.981 Q6TRW4 →
A1L1F4 0.981 A1L1F4 →
F8VPU6 0.980 F8VPU6 →
C0H906 0.980 C0H906 →
Q6GQD0 0.980 Q6GQD0 →
A4L9P7 0.980 A4L9P7 →
Q4VA53 0.980 Q4VA53 →
B4Q034 0.980 B4Q034 →
Q5R6J0 0.979 Q5R6J0 →
Q5F3U9 0.979 Q5F3U9 →
B3NU52 0.979 B3NU52 →
Q8N1I0 0.978 Q8N1I0 →
B4I0W6 0.978 B4I0W6 →
Q56A27 0.978 Q56A27 →
ECPAS Proteasome adapter and scaffold protein ECM29 0.978 landscape →
Q7PX35 0.978 Q7PX35 →
Q91WR3 0.978 Q91WR3 →
Q7TMY8 0.977 Q7TMY8 →
O94915 0.977 O94915 →
Q5F3V3 0.977 Q5F3V3 →
Q6DIE2 0.977 Q6DIE2 →
P59764 0.977 P59764 →